Dr Gulietta Pupo

Level A Research Only
Medicine, Westmead Clinical School

Telephone +61 2 9845 9052
Fax +61 2 9845 9102

Map

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Rizos, H., Menzies, A., Pupo, G., Carlino, M., Fung, C., Hyman, J., Haydu, L., Mijatov, B., Becker, T., Boyd, S., Howle, J., Saw, R., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2014). BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clinical Cancer Research, 20(7), 1965-1977. [More Information]
  • Carlino, M., Todd, J., Gowrishankar, K., Mijatov, B., Pupo, G., Fung, C., Snoyman, S., Hersey, P., Long, G., Kefford, R., Rizos, H. (2014). Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Molecular Oncology, 8(3), 544-554. [More Information]
  • Becker, T., Boyd, S., Mijatov, B., Gowrishankar, K., Snoyman, S., Pupo, G., Scolyer, R., Mann, G., Kefford, R., Zhang, X., Rizos, H. (2014). Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene, 33(9), 1158-1166. [More Information]
  • Parmenter, T., Kleinschmidt, M., Kinross, K., Bond, S., Li, J., Kaadige, M., Rao, A., Sheppard, K., Hugo, W., Pupo, G., Long, G., Scolyer, R., Rizos, H., et al (2014). Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discovery, 4(4), 423-433. [More Information]
  • Gallagher, S., Mijatov, B., Gunatilake, D., Tiffen, J., Gowrishankar, K., Jin, L., Pupo, G., Cullinane, C., Prinjha, R., Smithers, N., Rizos, H., Hersey, P., et al (2014). The Epigenetic Regulator I-BET151 Induces BIM Dependent Apoptosis and Cell Cycle Arrest OF Human Melanoma Cells. The Journal of Investigative Dermatology, 134(11), 1523-1747. [More Information]
  • Carlino, M., Gowrishankar, K., Saunders, C., Pupo, G., Snoyman, S., Zhang, X., Saw, R., Becker, T., Kefford, R., Long, G., Rizos, H. (2013). Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition Following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma. Molecular Cancer Therapeutics, 12(7), 1332-1342. [More Information]
  • Mann, G., Pupo, G., Campain, A., Carter, C., Schramm, S., Pianova, S., Gerega, S., Desilva, C., Lai, K., Wilmott, J., Hersey, P., Kefford, R., Thompson, J., Yang, J., Scolyer, R., et al (2013). BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. The Journal of Investigative Dermatology, 133(2), 509-517. [More Information]
  • Dutton-Regester, K., Kakavand, H., Aoude, L., Stark, M., Gartside, M., Johansson, P., O'Connor, L., Lanagan, C., Tembe, V., Pupo, G., Haydu, L., Mann, G., Thompson, J., Scolyer, R., et al (2013). Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. Pigment Cell and Melanoma Research, 26(6), 852-860. [More Information]
  • Boyd, S., Mijatov, B., Pupo, G., Tran, S., Gowrishankar, K., Shaw, H., Goding, C., Scolyer, R., Mann, G., Kefford, R., Rizos, H., Becker, T. (2013). Oncogenic B-RAF(V600E) Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion. The Journal of Investigative Dermatology, 133(5), 1269-1277. [More Information]
  • Fung, C., Pupo, G., Scolyer, R., Kefford, R., Rizos, H. (2013). p16INK4a deficiency promotes DNA hyper-replication and genetic instability in melanocytes. Pigment Cell and Melanoma Research, 26(2), 236-246. [More Information]
  • Dutton-Regester, K., Irwin, D., Hunt, P., Aoude, L., Tembe, V., Pupo, G., Lanagan, C., Carter, C., O'Connor, L., O'Rourke, M., Scolyer, R., Mann, G., et al (2012). A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma. Molecular Cancer Therapeutics, 11(4), 888-897. [More Information]
  • Zhou, L., Pupo, G., Gupta, P., Liu, B., Tran, S., Rahme, R., Wang, B., Rua, R., Rizos, H., Carroll, A., Saksena, N., et al (2012). A parallel genome-wide mRNA and microRNA profiling of the frontal cortex of HIV patients with and without HIV-associated dementia shows the role of axon guidance and downstream pathways in HIV-mediated neurodegeneration. BMC Genomics, 13(November), 1-17. [More Information]
  • Gowrishankar, K., Snoyman, S., Pupo, G., Becker, T., Kefford, R., Rizos, H. (2012). Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition. The Journal of Investigative Dermatology, 132(7), 1850-1859. [More Information]
  • Kim, J., McCarthy, S., Thompson, J., Pupo, G., Vonthethoff, L., Nash, P., Mann, G., Scolyer, R. (2012). Cellular blue naevus involving the urinary bladder. Pathology, 44(7), 664-668. [More Information]
  • Dutton-Regester, K., Aoude, L., Nancarrow, D., Stark, M., O'Connor, L., Lanagan, C., Pupo, G., Tembe, V., Carter, C., O'Rourke, M., Scolyer, R., Mann, G., et al (2012). Identification of TFG (TRK-Fused Gene) as a Putative Metastatic Melanoma Tumor Suppressor Gene. Genes Chromosomes and Cancer, 51(5), 452-461. [More Information]
  • Shi, H., Moriceau, G., Kong, X., Koya, R., Nazarian, R., Pupo, G., Bacchiocchi, A., Dahlman, K., Chmielowski, B., Sosman, J., Kefford, R., Long, G., et al (2012). Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors. Cancer Discovery, 2(5), 414-424. [More Information]
  • Balleine, R., Provan, P., Pupo, G., Pathmanathan, N., Cummings, M., Farshid, G., Salisbury, E., Bilous, M., Byth Wilson, K., kConFab Investigators., Mann, G. (2010). Familial Concordance of Breast Cancer Pathology as an Indicator of Genotype in Multiple-Case Families. Genes Chromosomes and Cancer, 49(12), 1082-1094. [More Information]
  • Scurr, L., Pupo, G., Becker, T., Lai, K., Schrama, D., Haferkamp, S., Irvine, M., Scolyer, R., Mann, G., Becker, J., Kefford, R., Rizos, H. (2010). IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence. Cell, 141(4), 717-727. [More Information]
  • Wong, E., Tesoriero, A., Pupo, G., Mann, G., KConFab, C., ABCFS, T., McCredie, M., Giles, G., Hopper, J., Hopper, G., et al (2008). Is MSH2 a breast cancer susceptibility gene? Familial Cancer, 7(2), 151-155. [More Information]
  • Lose, F., Arnold, J., Young, D., Brown, C., Mann, G., Pupo, G., Khanna, K., Chenevix-Trench, G., Spurdle, A. (2007). BCoR-L1 variation and breast cancer. Breast Cancer Research, 9(4), 1-12. [More Information]
  • Marsh, A., Healey, S., Lewis, A., Spurdle, A., Kedda, M., Khanna, K., Mann, G., Pupo, G., Lakhani, S., Chenevix-Trench, G. (2007). Mutation analysis of five candidate genes in familial breast cancer. Breast Cancer Research and Treatment, 105(3), 377-389. [More Information]
  • Mann, G., Pupo, G., Newman, B., Chenevix-Trench, G., McGuffog, L., Southey, M., Easton, D., Szabo, C., Renard, H., Odefrey, F., et al (2006). A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes and Cancer, 45(7). [More Information]
  • Mann, G., Thorne, H., Balleine, R., Butow, P., Clarke, C., Edkins, E., Evans, G., Fereday, S., Haan, E., Gattas, M., Kirk, J., Leary, J., Pupo, G., et al (2006). Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Research, 8(1), 1-15. [More Information]
  • Lose, F., Lovelock, P., Chenevix-Trench, G., Mann, G., Pupo, G., Spurdle, A. (2006). Variation in the RAD51 gene and familial breast cancer. Breast Cancer Research, 8(3), R26-R26. [More Information]
  • Lewis, A., Flanagan, J., Marsh, A., Pupo, G., Mann, G., Spurdle, A., Lindeman, G., Visvader, J., Brown, M., Chenevix-Trench, G., et al (2005). Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Research, 7(6), R1005-R1016. [More Information]
  • Chenevix-Trench, G., Spurdle, A., Gatei, M., Kelly, H., Marsh, A., Chen, X., Donn, K., Cummings, M., Nyholt, D., Jenkins, M., Pupo, G., Kirk, J., Tucker, P., Mann, G., et al (2002). Dominant Negative ATM Mutations in Breast Cancer Families. Journal of the National Cancer Institute, 94(3), 205-215.
  • Marsh, A., Spurdle, A., Turner, B., Fereday, S., Thorne, H., Pupo, G., Mann, G., Hopper, J., Sambrook, J., Chenevix-Trench, G., et al (2001). The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia. Breast Cancer Research, 3(5), 346-349.

2014

  • Rizos, H., Menzies, A., Pupo, G., Carlino, M., Fung, C., Hyman, J., Haydu, L., Mijatov, B., Becker, T., Boyd, S., Howle, J., Saw, R., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2014). BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clinical Cancer Research, 20(7), 1965-1977. [More Information]
  • Carlino, M., Todd, J., Gowrishankar, K., Mijatov, B., Pupo, G., Fung, C., Snoyman, S., Hersey, P., Long, G., Kefford, R., Rizos, H. (2014). Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Molecular Oncology, 8(3), 544-554. [More Information]
  • Becker, T., Boyd, S., Mijatov, B., Gowrishankar, K., Snoyman, S., Pupo, G., Scolyer, R., Mann, G., Kefford, R., Zhang, X., Rizos, H. (2014). Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene, 33(9), 1158-1166. [More Information]
  • Parmenter, T., Kleinschmidt, M., Kinross, K., Bond, S., Li, J., Kaadige, M., Rao, A., Sheppard, K., Hugo, W., Pupo, G., Long, G., Scolyer, R., Rizos, H., et al (2014). Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discovery, 4(4), 423-433. [More Information]
  • Gallagher, S., Mijatov, B., Gunatilake, D., Tiffen, J., Gowrishankar, K., Jin, L., Pupo, G., Cullinane, C., Prinjha, R., Smithers, N., Rizos, H., Hersey, P., et al (2014). The Epigenetic Regulator I-BET151 Induces BIM Dependent Apoptosis and Cell Cycle Arrest OF Human Melanoma Cells. The Journal of Investigative Dermatology, 134(11), 1523-1747. [More Information]

2013

  • Carlino, M., Gowrishankar, K., Saunders, C., Pupo, G., Snoyman, S., Zhang, X., Saw, R., Becker, T., Kefford, R., Long, G., Rizos, H. (2013). Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition Following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma. Molecular Cancer Therapeutics, 12(7), 1332-1342. [More Information]
  • Mann, G., Pupo, G., Campain, A., Carter, C., Schramm, S., Pianova, S., Gerega, S., Desilva, C., Lai, K., Wilmott, J., Hersey, P., Kefford, R., Thompson, J., Yang, J., Scolyer, R., et al (2013). BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. The Journal of Investigative Dermatology, 133(2), 509-517. [More Information]
  • Dutton-Regester, K., Kakavand, H., Aoude, L., Stark, M., Gartside, M., Johansson, P., O'Connor, L., Lanagan, C., Tembe, V., Pupo, G., Haydu, L., Mann, G., Thompson, J., Scolyer, R., et al (2013). Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. Pigment Cell and Melanoma Research, 26(6), 852-860. [More Information]
  • Boyd, S., Mijatov, B., Pupo, G., Tran, S., Gowrishankar, K., Shaw, H., Goding, C., Scolyer, R., Mann, G., Kefford, R., Rizos, H., Becker, T. (2013). Oncogenic B-RAF(V600E) Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion. The Journal of Investigative Dermatology, 133(5), 1269-1277. [More Information]
  • Fung, C., Pupo, G., Scolyer, R., Kefford, R., Rizos, H. (2013). p16INK4a deficiency promotes DNA hyper-replication and genetic instability in melanocytes. Pigment Cell and Melanoma Research, 26(2), 236-246. [More Information]

2012

  • Dutton-Regester, K., Irwin, D., Hunt, P., Aoude, L., Tembe, V., Pupo, G., Lanagan, C., Carter, C., O'Connor, L., O'Rourke, M., Scolyer, R., Mann, G., et al (2012). A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma. Molecular Cancer Therapeutics, 11(4), 888-897. [More Information]
  • Zhou, L., Pupo, G., Gupta, P., Liu, B., Tran, S., Rahme, R., Wang, B., Rua, R., Rizos, H., Carroll, A., Saksena, N., et al (2012). A parallel genome-wide mRNA and microRNA profiling of the frontal cortex of HIV patients with and without HIV-associated dementia shows the role of axon guidance and downstream pathways in HIV-mediated neurodegeneration. BMC Genomics, 13(November), 1-17. [More Information]
  • Gowrishankar, K., Snoyman, S., Pupo, G., Becker, T., Kefford, R., Rizos, H. (2012). Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition. The Journal of Investigative Dermatology, 132(7), 1850-1859. [More Information]
  • Kim, J., McCarthy, S., Thompson, J., Pupo, G., Vonthethoff, L., Nash, P., Mann, G., Scolyer, R. (2012). Cellular blue naevus involving the urinary bladder. Pathology, 44(7), 664-668. [More Information]
  • Dutton-Regester, K., Aoude, L., Nancarrow, D., Stark, M., O'Connor, L., Lanagan, C., Pupo, G., Tembe, V., Carter, C., O'Rourke, M., Scolyer, R., Mann, G., et al (2012). Identification of TFG (TRK-Fused Gene) as a Putative Metastatic Melanoma Tumor Suppressor Gene. Genes Chromosomes and Cancer, 51(5), 452-461. [More Information]
  • Shi, H., Moriceau, G., Kong, X., Koya, R., Nazarian, R., Pupo, G., Bacchiocchi, A., Dahlman, K., Chmielowski, B., Sosman, J., Kefford, R., Long, G., et al (2012). Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors. Cancer Discovery, 2(5), 414-424. [More Information]

2010

  • Balleine, R., Provan, P., Pupo, G., Pathmanathan, N., Cummings, M., Farshid, G., Salisbury, E., Bilous, M., Byth Wilson, K., kConFab Investigators., Mann, G. (2010). Familial Concordance of Breast Cancer Pathology as an Indicator of Genotype in Multiple-Case Families. Genes Chromosomes and Cancer, 49(12), 1082-1094. [More Information]
  • Scurr, L., Pupo, G., Becker, T., Lai, K., Schrama, D., Haferkamp, S., Irvine, M., Scolyer, R., Mann, G., Becker, J., Kefford, R., Rizos, H. (2010). IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence. Cell, 141(4), 717-727. [More Information]

2008

  • Wong, E., Tesoriero, A., Pupo, G., Mann, G., KConFab, C., ABCFS, T., McCredie, M., Giles, G., Hopper, J., Hopper, G., et al (2008). Is MSH2 a breast cancer susceptibility gene? Familial Cancer, 7(2), 151-155. [More Information]

2007

  • Lose, F., Arnold, J., Young, D., Brown, C., Mann, G., Pupo, G., Khanna, K., Chenevix-Trench, G., Spurdle, A. (2007). BCoR-L1 variation and breast cancer. Breast Cancer Research, 9(4), 1-12. [More Information]
  • Marsh, A., Healey, S., Lewis, A., Spurdle, A., Kedda, M., Khanna, K., Mann, G., Pupo, G., Lakhani, S., Chenevix-Trench, G. (2007). Mutation analysis of five candidate genes in familial breast cancer. Breast Cancer Research and Treatment, 105(3), 377-389. [More Information]

2006

  • Mann, G., Pupo, G., Newman, B., Chenevix-Trench, G., McGuffog, L., Southey, M., Easton, D., Szabo, C., Renard, H., Odefrey, F., et al (2006). A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes and Cancer, 45(7). [More Information]
  • Mann, G., Thorne, H., Balleine, R., Butow, P., Clarke, C., Edkins, E., Evans, G., Fereday, S., Haan, E., Gattas, M., Kirk, J., Leary, J., Pupo, G., et al (2006). Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Research, 8(1), 1-15. [More Information]
  • Lose, F., Lovelock, P., Chenevix-Trench, G., Mann, G., Pupo, G., Spurdle, A. (2006). Variation in the RAD51 gene and familial breast cancer. Breast Cancer Research, 8(3), R26-R26. [More Information]

2005

  • Lewis, A., Flanagan, J., Marsh, A., Pupo, G., Mann, G., Spurdle, A., Lindeman, G., Visvader, J., Brown, M., Chenevix-Trench, G., et al (2005). Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Research, 7(6), R1005-R1016. [More Information]

2002

  • Chenevix-Trench, G., Spurdle, A., Gatei, M., Kelly, H., Marsh, A., Chen, X., Donn, K., Cummings, M., Nyholt, D., Jenkins, M., Pupo, G., Kirk, J., Tucker, P., Mann, G., et al (2002). Dominant Negative ATM Mutations in Breast Cancer Families. Journal of the National Cancer Institute, 94(3), 205-215.

2001

  • Marsh, A., Spurdle, A., Turner, B., Fereday, S., Thorne, H., Pupo, G., Mann, G., Hopper, J., Sambrook, J., Chenevix-Trench, G., et al (2001). The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia. Breast Cancer Research, 3(5), 346-349.

To update your profile click here. For support on your academic profile contact .